Citigroup Inc Chimerix Inc Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.9 - $1.06 $162 - $191	-181 Reduced 90.05%	20 $0
Q2 2023 Aug 10, 2023	BUY	$1.1 - $1.54 $22 - $30	20 Added 11.05%	201 $0
Q1 2023 May 11, 2023	SELL	$1.19 - $2.09 $7,821 - $13,737	-6,573 Reduced 97.32%	181 $0
Q4 2022 Feb 09, 2023	SELL	$1.67 - $2.35 $2,279 - $3,207	-1,365 Reduced 16.81%	6,754 $12,000
Q3 2022 Nov 10, 2022	SELL	$1.81 - $2.76 $783 - $1,195	-433 Reduced 5.06%	8,119 $16,000
Q2 2022 Aug 10, 2022	SELL	$1.34 - $5.34 $49,234 - $196,202	-36,742 Reduced 81.12%	8,552 $18,000
Q1 2022 May 12, 2022	SELL	$4.58 - $6.8 $688,071 - $1.02 Million	-150,234 Reduced 76.84%	45,294 $207,000
Q4 2021 Feb 10, 2022	BUY	$5.23 - $7.18 $558,590 - $766,859	106,805 Added 120.38%	195,528 $1.26 Million
Q3 2021 Nov 10, 2021	BUY	$5.94 - $8.75 $527,014 - $776,326	88,723 New	88,723 $549,000

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.